Trade PRME stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Prime Medicine, Inc. (PRME) is trading at US$3.63, down 8.92% today as of Oct 12, 14:08 EDT. The company has a market capitalisation of US$614.87M. Over the past 52 weeks, PRME has traded between US$2.67 and US$6.65. On Syfe you can trade PRME with $0 commission and add it to your watchlist.
| Previous close | US$3.99 |
|---|---|
| Market cap | US$614.87M |
| 52-week range | US$2.67 – US$6.65 |
| Volume | 8.07M |
| Exchange | US |
Prime Medicine, Inc.
Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.
Year: 2022
Update: Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration; Shares Rise
Jul 8, 6:08 PM · MT Newswires
Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration
Jul 8, 4:02 PM · MT Newswires
Prime Medicine, Inc. (PRME) stock is trading at US$3.63, -8.92% from the previous close of US$3.99.
The market cap for Prime Medicine, Inc. (PRME) stock is approximately US$614.87M.
The 52-week high for Prime Medicine, Inc. (PRME) stock is US$6.65.
The 52-week low for Prime Medicine, Inc. (PRME) stock is US$2.67.
Prime Medicine, Inc. (PRME) does not currently pay a dividend.
Stay on top of PRME
Price moves, news and earnings — straight to your inbox.
Snapshot
Popular Stocks in Singapore
